CROMOLYN SODIUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H14O11.2Na
Molecular Weight	512.3302
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[Na+].OC(COC1=CC=CC2=C1C(=O)C=C(O2)C([O-])=O)COC3=CC=CC4=C3C(=O)C=C(O4)C([O-])=O

InChI

InChIKey=VLARUOGDXDTHEH-UHFFFAOYSA-L

InChI=1S/C23H16O11.2Na/c24-11(9-31-14-3-1-5-16-20(14)12(25)7-18(33-16)22(27)28)10-32-15-4-2-6-17-21(15)13(26)8-19(34-17)23(29)30;;/h1-8,11,24H,9-10H2,(H,27,28)(H,29,30);;/q;2*+1/p-2

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/anda/2000/75-271_Cromolyn%20Sodium_prntlbl.pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2004/18887slr020_intal_lbl.pdf
Curator's Comment: description was created based on several sources, including: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/090954s000lbl.pdf |http://www.rxlist.com/crolom-drug.htm | https://www.ncbi.nlm.nih.gov/pubmed/8809432

Cromolyn is a mast cell stabilizer. In vitro and in vivo animal studies have shown that cromolyn sodium inhibits the degranulation of sensitized mast cells, which occurs after exposure to specific antigens. Cromolyn sodium acts by inhibiting the release of histamine and SRS-A (slow-reacting substance of anaphylaxis) from the mast cell. Cromolyn is indicated in the management of patients with mastocytosis, prophylaxis (long-term control) of bronchial asthma, prevention of exercise-induced bronchospasm, prevention and treatment of seasonal and perennial allergic rhinitis The most frequently reported adverse reactions attributed to cromolyn sodium treatment were: throat irritation or dryness, bad taste, cough, wheeze, nausea.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
G-protein coupled receptor 35 11 Target ID: CHEMBL1293267 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22218743 \| https://www.ncbi.nlm.nih.gov/pubmed/3110245	Agonist 2678
Chloride channels 4 Target ID: Chloride channels Sources: https://www.ncbi.nlm.nih.gov/pubmed/1280136	Blocker 537	19.0 µM [IC50]
calcium ion import 8 Target ID: GO:0070509 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/18887slr020_intal_lbl.pdf	Blocker 537
mast cell activation 6 Target ID: GO:0045576 Sources: http://www.ncbi.nlm.nih.gov/pubmed/12396022	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Mastocytosis 6 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/090954s000lbl.pdf	Primary	Approved 8429	CROMOLYN SODIUM Approved Use GASTROCROM is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients. Launch Date 1994
Bronchial asthma 50 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2004/18887slr020_intal_lbl.pdf	Preventing	Approved 8429	CROMOLYN SODIUM Approved Use Cromolyn sodium is a prophylactic agent indicated in the management of patients with bronchial asthma. Launch Date 1994
Allergic rhinitis 100 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/anda/2001/75-702_Cromolyn%20Sodium_prntlbl.pdf	Palliative	Approved 8429	CROMOLYN SODIUM Approved Use Cromolyn sodium is used to prevent and relieve nasal symptoms of hay fever and other nasal allergies. Launch Date 1994
Vernal keratoconjunctivitis 6 Sources: http://www.rxlist.com/crolom-drug.htm	Primary	Approved 8429	CROMOLYN SODIUM Approved Use Cromolyn sodium ophthalmic solution is indicated in the treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis. Launch Date 1994
Asthma 241 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/anda/2000/75-271_Cromolyn%20Sodium_prntlbl.pdf	Preventing	Approved 8429	CROMOLYN SODIUM Approved Use To help prevent asthma attacks. Launch Date 1994
Allergic rhinitis 100 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b34d36ca-4df4-458c-af0f-c0d0c9a025d9	Preventing	Approved 8429	NASALCROM Approved Use To prevent and relieve nasal symptoms of hay fever and other nasal allergies Launch Date 1997
Allergic conjunctivitis 100 Sources: https://www.medicines.org.uk/emc/PIL.31398.latest.pdf	Palliative	Approved 8429	OPTREX Approved Use Optrex is used for the prevention and treatment of eye allergies.

C_max

Value	Dose	Co-administered	Analyte	Population
0.24 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28856569/	17.1 mg single, respiratory dose: 17.1 mg route of administration: Respiratory experiment type: SINGLE co-administered: IBUPROFEN	IBUPROFEN	CROMOLYN cerebrospinal fluid	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
0.34 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28856569/	34.2 mg single, respiratory dose: 34.2 mg route of administration: Respiratory experiment type: SINGLE co-administered: IBUPROFEN	IBUPROFEN	CROMOLYN cerebrospinal fluid	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
46.69 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28856569/	17.1 mg single, respiratory dose: 17.1 mg route of administration: Respiratory experiment type: SINGLE co-administered: IBUPROFEN	IBUPROFEN	CROMOLYN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
96.75 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28856569/	34.2 mg single, respiratory dose: 34.2 mg route of administration: Respiratory experiment type: SINGLE co-administered: IBUPROFEN	IBUPROFEN	CROMOLYN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
156 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32944204/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		CROMOLYN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
236 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32944204/	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:		CROMOLYN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
338 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32944204/	40 mg single, oral dose: 40 mg route of administration: Oral experiment type: SINGLE co-administered:		CROMOLYN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
526 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32944204/	80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered:		CROMOLYN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
1.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28856569/	17.1 mg single, respiratory dose: 17.1 mg route of administration: Respiratory experiment type: SINGLE co-administered: IBUPROFEN	IBUPROFEN	CROMOLYN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/28856569/	34.2 mg single, respiratory dose: 34.2 mg route of administration: Respiratory experiment type: SINGLE co-administered: IBUPROFEN	IBUPROFEN	CROMOLYN plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
62.4 mg 1 times / day multiple, intranasal Dose: 62.4 mg, 1 times / day Route: intranasal Route: multiple Dose: 62.4 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/402406	unhealthy, 25 years (range: 5-51 years) n = 45 Health Status: unhealthy Age Group: 25 years (range: 5-51 years) Sex: M+F Population Size: 45 Sources: https://pubmed.ncbi.nlm.nih.gov/402406	Sources: https://pubmed.ncbi.nlm.nih.gov/402406
200 mg 4 times / day multiple, oral Recommended Dose: 200 mg, 4 times / day Route: oral Route: multiple Dose: 200 mg, 4 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/090954s000lbl.pdf	unhealthy, adult Health Status: unhealthy Condition: mastocytosis Age Group: adult Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/090954s000lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/090954s000lbl.pdf
2 % multiple, ophthalmic Dose: 2 % Route: ophthalmic Route: multiple Dose: 2 % Sources: https://pubmed.ncbi.nlm.nih.gov/22118312	unhealthy, adult n = 37 Health Status: unhealthy Condition: allergic conjunctivitis Age Group: adult Population Size: 37 Sources: https://pubmed.ncbi.nlm.nih.gov/22118312	Sources: https://pubmed.ncbi.nlm.nih.gov/22118312

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP 270

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP 270	substrate 3367 Sources: https://pdf.hres.ca/dpd_pm/00015714.PDF#page=2 Page: 2.0	no

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B2-1127	http://www.3bsc.com/index/pro_info.php?id=54843
AHH Chemical co.,ltd	MT-00052	http://www.ahhchemical.com/product/MT-00052.html
AK Scientific, Inc. (AKSCI)	O542	http://www.aksci.com/item_detail.php?cat=O542
Acadechem	ACDC-030058	http://acadechemical.com/product/1820
Achemo Scientific Limited	AC-85374	http://www.achemo.com/search/?Keyword= 16110-51-3
Ambeed	A839184	https://www.ambeed.com/products/16110-51-3.html
Ambinter	Amb20243267	http://www.ambinter.com/reference/20243267
Angene	AGN-PC-07Y4GQ	http://www.angenechemical.com/productshow/AGN-PC-07Y4GQ.html
Anward	ANW-71958	http://www.anward.com/pro_result/58409
Aurora Fine Chemicals LLC	A13.110.125	http://online.aurorafinechemicals.com/info?ID=A13.110.125
BLD Pharm	BD53784	http://www.bldpharm.com/products/16110-51-3.html
BioSynth	J-009783	https://www.biosynth.com/en/products/all-products/products/J-009783.html
CSNpharm	CSN17084	https://www.csnpharm.com/products/cromolyn.html
ChemMol	30102492	http://www.chemmol.com/chemmol/30102492.html
ChemMol	44002046	http://www.chemmol.com/chemmol/44002046.html
Chemspace	CSSS00020617570	https://chem-space.com/CSSS00020617570
Clearsynth	CS-L-00099	https://www.clearsynth.com/en/CSL00099.html
DC Chemicals	DC20926	http://www.dcchemicals.com/product_show-DC20926.html
Finetech	FT-0601561	http://www.finetechnology-ind.com/prod/detail/pub/16110-51-3.html
Matrix Scientific	97021	https://www.matrixscientific.com/097021.html
MolPort	MolPort-005-934-024	https://www.molport.com/shop/molecule-link/MolPort-005-934-024
Smolecule	S591882	https://www.smolecule.com/products/s591882
THE BioTek	bt-315145	https://www.thebiotek.com/product/others/bt-315145
abcr GmbH	AB540456	http://www.abcr.com/shop/en/AB540456
eNovation Chemicals	D926914	https://www.enovationchem.com/ProductDetails.asp?ProductID=D926914

PubMed

Title	Date	PubMed
[Changes in biochemical inflammation markers in evaluation of the effectiveness of basic chemotherapy in bronchial asthma].	2001	11417175
Ultrasonic nebulization system for respiratory drug delivery.	2001	11247278
Comparative functional characterization of mouse bone marrow-derived mast cells and peritoneal mast cells in response to non-immunological stimuli.	2001 Apr	11491575
Impact of inhaled antiinflammatory therapy on hospitalization and emergency department visits for children with asthma.	2001 Apr	11335748
Cyclo-oxygenase and lipoxygenase pathways in mast cell dependent-neurogenic inflammation induced by electrical stimulation of the rat saphenous nerve.	2001 Apr	11264253
Management of asthma in children.	2001 Apr 1	11310649
Management of pyoderma gangrenosum.	2001 Apr 15	11327344
Antibacterial activity of apical surface fluid from the human airway cell line Calu-3: pharmacologic alteration by corticosteroids and beta(2)-agonists.	2001 Aug	11509329
Asthma symptoms, morbidity, and antiinflammatory use in inner-city children.	2001 Aug	11483788
[Inhalation therapy].	2001 Dec	11937990
Role of mast cells in zymosan-induced peritoneal inflammation in Balb/c and mast cell-deficient WBB6F1 mice.	2001 Jan	11200065
Acute stress increases permeability of the blood-brain-barrier through activation of brain mast cells.	2001 Jan 5	11146058
Asthma in the hospitalized obstetrical patient.	2001 Jun	11413902
Role of mast cells in antigen-induced airway inflammation and bronchial hyperresponsiveness in rats.	2001 Mar	11325017
Therapy choices beyond antihistamines. Vasomotor rhinitis.	2001 Nov	12420500
[Inhaled corticosteroid therapy in childhood asthma].	2001 Oct	11676147
Sodium cromoglycate attenuates pulmonary inflammation without influencing bronchial responsiveness in healthy subjects exposed to organic dust.	2001 Sep	11591185
Inhaled sodium cromoglycate in the management of asthma: should it be consigned to history?	2001 Sep	11591181
From khellin to sodium cromoglycate--a tribute to the work of Dr. R. E. C. Altounyan (1922-1987).	2002 Jan	11836935
The combination of nebulized sodium cromoglycate and salbutamol in the treatment of moderate-to-severe asthma in children.	2002 Jun	12144644
Ischaemic preconditioning and mast cell histamine release: microdialysis of isolated rat hearts.	2002 May	12123626
Inhalation and deposition of nebulized sodium cromoglycate in two different particle size distributions in children with asthma.	2002 Nov	12357479

Patents

Sample Use Guides

In Vivo Use Guide

Two metered inhalations four times daily at regular intervals (asthma).

Route of Administration: Respiratory

In Vitro Use Guide

Cromoglycate (the active component of cromoglicate lisetil) significantly inhibits histamine release from lung and tonsillar mast cells at 1000 uM.

Name

Type

Language

CROMOLYN SODIUM

Official Name

English

DISODIUM 5,5'-((2-HYDROXYTRIMETHYLENE)DIOXY)BIS(4-OXO-4H-1-BENZOPYRAN-2-CARBOXYLATE)

Systematic Name

English

SODIUM CROMOGLICATE [JAN]

Common Name

English

NASALCROM

Brand Name

English

DISODIUM CROMOLYN

Official Name

English

NSC-109500

Code

English

INTAL

Brand Name

English

GASTROCROM

Brand Name

English

CROMOLYN SODIUM [USP MONOGRAPH]

Common Name

English

CROLOM

Brand Name

English

OPTICROM

Brand Name

English

CROMOLYN SODIUM [VANDF]

Common Name

English

SODIUM CROMOGLICATE [EP MONOGRAPH]

Common Name

English

NATRII CROMOGLICAS [WHO-IP LATIN]

Common Name

English

FPL.670

Code

English

CROMOLYN SODIUM [USP-RS]

Common Name

English

4H-1-BENZOPYRAN-2-CARBOXYLIC ACID, 5,5'-((2-HYDROXY-1,3-PROPANEDIYL)BIS(OXY))BIS(4-OXO-, DISODIUM SALT)

Common Name

English

SODIUM CROMOGLYCATE

Common Name

English

CROMOLYN SODIUM [ORANGE BOOK]

Common Name

English

CROMOGLICATE SODIUM

Common Name

English

FPL-670

Code

English

SODIUM CROMOGLICATE [WHO-IP]

Common Name

English

DISODIUM CROMOLYN [INCI]

Common Name

English

CROMOLYN SODIUM [USAN]

Common Name

English

CROMOPTIC

Brand Name

English

SODIUM CROMOGLICATE [MART.]

Common Name

English

SODIUM CROMOGLICATE

Common Name

English

CROMOLYN DISODIUM SALT [MI]

Common Name

English

Cromoglicate sodium [WHO-DD]

Common Name

English

SODIUM CROMOLYN

Common Name

English

ASTILYN

Brand Name

English

Classification Tree Code System Code

WHO-VATC

QR03AK05